Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
Autolus Therapeutics (Nasdaq: AUTL) will release its second quarter 2026 financial results and operational highlights before U.S. market open on Tuesday, August 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will release its second quarter 2026 financial results and operational highlights before U.S. market open on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST, with pre-registration required for dial-in details, and a live webcast plus replay available in the events section of the company’s website.
Details
News Market Reaction – AUTL
On Aug 4, the first trading day after this news, AUTL closed 7.14% above the previous close. Argus tracked a peak move of +5.8% during that session. Our momentum scanner recorded 25 alerts for this stock that day. That session’s volume was 2.4x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Aug 4 session.
Key Figures
- Reporting period
- Q2 2026
- Financial results and operational highlights
- Results release date
- August 11, 2026
- Before open of U.S. markets
- Conference call time
- 8:30am EDT / 1:30pm BST
- Management discussion of financial results and business update
Previous Conferences,earnings date Reports
-
First-quarter 2026 results date and conference call announcement
-
Fourth-quarter and full-year 2025 results date announcement
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.
Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.